Advertisement

Internal and Emergency Medicine

, Volume 14, Issue 1, pp 1–3 | Cite as

Silybin and metabolic disorders

  • Pasquale PignatelliEmail author
  • Roberto Carnevale
  • Danilo Menichelli
IM - COMMENTARY
  • 109 Downloads
Mediterranean diet represents a fundamental strategy in the prevention of cardiovascular and metabolic disorders as demonstrated by observational and interventional trials [ 1]. Among the most represented elements of the Mediterranean diet are polyphenols that display protective effects on cardiometabolic disorders by counteracting oxidative stress that represent a key point of the preventive strategy in this setting. Hence, oxidative stress seems to be involved in both cardiovascular and metabolic disorders [ 2]. Indeed, atherosclerotic disease is associated with increased level of oxidative stress [ 3] as well as metabolic disorders such as non-alcoholic fatty liver disease (NAFLD) [ 4] and diabetes [ 5] (Fig.  1).

Notes

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Statement on human and animal rights

This article does not contain any studies with human participants or animals performed by any of the authors.

Informed consent

None.

References

  1. 1.
    Violi F, Pignatelli P, Basili S (2010) Nutrition, supplements, and vitamins in platelet function and bleeding. Circulation 121(8):1033–1044.  https://doi.org/10.1161/CIRCULATIONAHA.109.880211 CrossRefPubMedGoogle Scholar
  2. 2.
    Violi F, Pignatelli P (2012) Platelet oxidative stress and thrombosis. Thromb Res 129(3):378–381.  https://doi.org/10.1016/j.thromres.2011.12.002 CrossRefPubMedGoogle Scholar
  3. 3.
    Violi F, Pignatelli P, Pignata C, Plebani A, Rossi P, Sanguigni V, Carnevale R, Soresina A, Finocchi A, Cirillo E, Catasca E, Angelico F, Loffredo L (2013) Reduced atherosclerotic burden in subjects with genetically determined low oxidative stress. Arterioscler Thromb Vasc Biol 33(2):406–412.  https://doi.org/10.1161/ATVBAHA.112.300438 CrossRefPubMedGoogle Scholar
  4. 4.
    Polimeni L, Del Ben M, Baratta F, Perri L, Albanese F, Pastori D, Violi F, Angelico F (2015) Oxidative stress: new insights on the association of non-alcoholic fatty liver disease and atherosclerosis. World J Hepatol 7(10):1325–1336.  https://doi.org/10.4254/wjh.v7.i10.1325 CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Santilli F, Lapenna D, La Barba S, Davi G (2015) Oxidative stress-related mechanisms affecting response to aspirin in diabetes mellitus. Free Radical Biol Med 80:101–110.  https://doi.org/10.1016/j.freeradbiomed.2014.12.010 CrossRefGoogle Scholar
  6. 6.
    Sciacqua A, Perticone M, Tripepi G, Addesi D, Cassano V, Maio R, Sesti G, Perticone F (2018) Metabolic and vascular effects of silybin in hypertensive patients with high one-hour post-load plasma glucose. Intern Emerg Med.  https://doi.org/10.1007/s11739-018-1951-6 CrossRefPubMedGoogle Scholar
  7. 7.
    Loguercio C, Festi D (2011) Silybin and the liver: from basic research to clinical practice. World J Gastroenterol 17(18):2288–2301.  https://doi.org/10.3748/wjg.v17.i18.2288 CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Trouillas P, Marsal P, Svobodova A, Vostalova J, Gazak R, Hrbac J, Sedmera P, Kren V, Lazzaroni R, Duroux JL, Walterova D (2008) Mechanism of the antioxidant action of silybin and 2,3-dehydrosilybin flavonolignans: a joint experimental and theoretical study. J Phys Chem A 112(5):1054–1063.  https://doi.org/10.1021/jp075814h CrossRefPubMedGoogle Scholar
  9. 9.
    Lirussi F, Beccarello A, Zanette G, De Monte A, Donadon V, Velussi M, Crepaldi G (2002) Silybin-beta-cyclodextrin in the treatment of patients with diabetes mellitus and alcoholic liver disease. Efficacy study of a new preparation of an anti-oxidant agent. Diabetes Nutr Metab 15(4):222–231PubMedGoogle Scholar
  10. 10.
    Huseini HF, Larijani B, Heshmat R, Fakhrzadeh H, Radjabipour B, Toliat T, Raza M (2006) The efficacy of Silybum marianum (L.) Gaertn. (silymarin) in the treatment of type II diabetes: a randomized, double-blind, placebo-controlled, clinical trial. Phytother Res 20(12):1036–1039.  https://doi.org/10.1002/ptr.1988 CrossRefPubMedGoogle Scholar
  11. 11.
    Federico A, Trappoliere M, Tuccillo C, de Sio I, Di Leva A, Del Vecchio Blanco C, Loguercio C (2006) A new silybin-vitamin E-phospholipid complex improves insulin resistance and liver damage in patients with non-alcoholic fatty liver disease: preliminary observations. Gut 55(6):901–902.  https://doi.org/10.1136/gut.2006.091967 CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Germano G, Sanguigni V, Pignatelli P, Caccese D, Lenti L, Ragazzo M, Lauro R, Violi F (2004) Enhanced platelet release of superoxide anion in systemic hypertension: role of AT1 receptors. J Hypertens 22(6):1151–1156CrossRefPubMedGoogle Scholar

Copyright information

© Società Italiana di Medicina Interna 2018

Authors and Affiliations

  • Pasquale Pignatelli
    • 1
    Email author
  • Roberto Carnevale
    • 2
  • Danilo Menichelli
    • 1
  1. 1.Department of Internal Medicine and Medical Specialties, I Clinica MedicaAtherothrombosis Centre, Sapienza University of RomeRomeItaly
  2. 2.Department of Medical-Surgical Sciences and BiotechnologiesSapienza University of RomeLatinaItaly

Personalised recommendations